| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 02/25/2009 | EP2026841A2 Conjugation process for pnag and a carrier protein |
| 02/25/2009 | EP2026838A2 A METHOD FOR DELIVERING A HUMAN CHORIONIC GONADOTROPIN (hCG) VACCINE FOR LONG-ACTING ANTIBODY PRODUCTION |
| 02/25/2009 | EP2026837A2 Antibodies as t cell receptor mimics, methods of production and uses thereof |
| 02/25/2009 | EP2026836A2 Peptide therapy |
| 02/25/2009 | EP2026820A1 Compositions comprising chitin microparticles and their medical uses |
| 02/25/2009 | EP2026806A2 Use of vx-702 for treating rheumatoid arthritis |
| 02/25/2009 | EP1551451B1 Use of escherichia coli heat labile toxin as an adjuvant in poultry |
| 02/25/2009 | EP1439857B1 USE OF BISPECIFIC ANTIBODIES BINDING TO THE ACTIVATING RECEPTOR FcEpsilonRI AND TO THE INHIBITING RECEPTOR OX2Ra (CD200Ra) TO REGULATE IMMUNE RESPONSES |
| 02/25/2009 | EP1345495B1 Methods for generating genetically altered antibody-producing cell lines with improved antibody characteristics |
| 02/25/2009 | EP1240326B1 Triggering receptor involved in natural cytotoxicity mediated by human natural killer cells and antibodies that identify this receptor |
| 02/25/2009 | EP1075277B1 Methods for detecting and inhibiting angiogenesis |
| 02/25/2009 | EP0815141B2 Antibodies active against a fusion polypeptide comprising a histidine portion |
| 02/25/2009 | EP0698216B2 Methods of typing hepatitis c virus and reagents for use therein |
| 02/25/2009 | CN101375160A Potentiation of apoptosis by monoclonal antibodies |
| 02/25/2009 | CN101374863A Immunoglobulins directed against NOGO |
| 02/25/2009 | CN101374859A A novel surface exposed haemophilus influenzae protein (protein e; pE) |
| 02/25/2009 | CN101374858A Polyvalent chimeric OSPC vaccinogen and diagnostic antigen |
| 02/25/2009 | CN101374551A Novel glycolipid adjuvant compositions |
| 02/25/2009 | CN101374550A Strain independent amplification of pathogens and vaccines thereto |
| 02/25/2009 | CN101374549A Conjugate vaccines |
| 02/25/2009 | CN101374548A Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates |
| 02/25/2009 | CN101374547A Vaccine for in ovo inoculation |
| 02/25/2009 | CN101374546A Multivalent immunoglobulin-based bioactive assemblies |
| 02/25/2009 | CN101374545A Elimination of heterogeneous or mixed cell population in tumors |
| 02/25/2009 | CN101374522A ANG2 and VEGF inhibitor combinations |
| 02/25/2009 | CN101374502A Medicament for topical use |
| 02/25/2009 | CN101372511A Immunogenic peptide composition for the prevention and treatment of alzheimer's disease |
| 02/25/2009 | CN101371924A Therapy of autoimmune disease in a patient with an inadequate response to a TNF-ALPHA inhibitor |
| 02/25/2009 | CN101371923A BAFF receptor (BCMA), an immunoregulatory agent |
| 02/25/2009 | CN101371922A Water-bearing liquid transformation reaction vaccine formulation for oral mucous membrane administration |
| 02/25/2009 | CN101371851A Immunity enhancement use of wintercherry fruit polysaccharide |
| 02/25/2009 | CN100464566C Method and equipment of changed digital color image |
| 02/25/2009 | CN100463964C Hybridization immune deficiency virus strain and application |
| 02/25/2009 | CN100463694C Virus coat protein/receptor chimeras and methods of use |
| 02/24/2009 | US7495091 Polynucleotides encoding novel proteins in enteroaggregative Escherichia coli (EAEC) useful for diagnosis and therapy of EAEC infections |
| 02/24/2009 | US7495090 An antitumor agent of polynucleotide sequence, a vector, a genetic construct, for encoding a protein |
| 02/24/2009 | US7495086 TWEAK receptor |
| 02/24/2009 | US7495085 Immunoglobulin for use in diagnosis, prevention and treatment of allergies, autoimmune, inflammatory and cell proliferative disorders |
| 02/24/2009 | US7495083 PRO940 antibodies |
| 02/24/2009 | US7495081 Framework patched anti-CD20 antibody |
| 02/24/2009 | US7495079 A polypeptide covalently attached with a polyethylene glycol propionaldehyde group having anti-hepatitis C activity |
| 02/24/2009 | US7495078 A polypeptide covalently attached with a polyethylene glycol propionaldehyde group having anti-hepatitis C activity |
| 02/24/2009 | US7495077 Homogeneous preparations of IL-28 and IL-29 |
| 02/24/2009 | US7495074 Single-stranded polynucleotides that code for human melanoma antigen(MAGE) and human leukocyte antigens, used in gene therapy and medical diagnosis; immunology |
| 02/24/2009 | US7494975 A polyanion selected from a heparin, a dextran, a pentosan, resobene, curdian sulfate, or 2-naphthalene sulfonate polymer and a CD4 polypeptide with a beta-hairpin confirmation; blocking HIV interaction with coreceptors |
| 02/24/2009 | US7494973 Therapeutic fibrin-derived peptides and uses thereof |
| 02/24/2009 | US7494812 Transforming lymphocytes with vector comprising gene sequences which code cytolethal distending toxin (cdt), leukotoxins and heat shock protein and generating regulatory cell which can be used to treat and/or prevent transplant rejection, autoimmune and inflammatory diseases; immunotherapy |
| 02/24/2009 | US7494810 Method for accessing microbial diversity |
| 02/24/2009 | US7494808 Methods and interferon deficient substrates for the propagation of viruses |
| 02/24/2009 | US7494799 Paramunity inducers based on attenuated rabbit myxoma virus |
| 02/24/2009 | US7494785 Recombinant subunit vaccine |
| 02/24/2009 | US7494774 Assay and compositions for detection of Bacillus anthracis nucleic acid |
| 02/24/2009 | US7494669 Delivery of physiological agents with in-situ gels comprising anionic polysaccharides |
| 02/24/2009 | US7494661 Methods for using tetanus toxin for beneficial purposes in animals (mammals) |
| 02/24/2009 | US7494659 Live attenuated influenza vaccine |
| 02/24/2009 | US7494658 Papilloma virus truncated L1 protein and fusion protein constructs |
| 02/24/2009 | US7494656 virus-like particle comprising at least one protein and mutein bound to influenza antigens or epitopes, used for inducing immune responsesv in particular antibody responses and for prevention or treatment of infections, allergies, cancer, drug addiction and poisoning |
| 02/24/2009 | US7494655 antigenic peptides, antibodies and carriers, diluents, excipients, adjuvants or auxiliary agents, use for inhibiting the formation of beta-amyloid; treatment of Alzheimer's disease or Down's syndrome |
| 02/24/2009 | US7494654 Compositions and methods for treating cardiovascular conditions with botulinum toxin |
| 02/24/2009 | US7494653 Inoculating a patient with an effective amount of PcrV antigen; monoclonal antibodies specific for the PcrV antigen |
| 02/24/2009 | US7494652 polyclonal antibodies comprising tumor necrosis factor, b-cell differentiation factor and interferon antibodies, directed to cytokines, used for treatment of septic shock in animals, including humans |
| 02/24/2009 | US7494651 monoclonal antibodies or antigen-binding fragments, that neutralize mature human transforming growth factors, useful for treating cell proliferative disorders in mammals |
| 02/24/2009 | US7494650 Monoclonal antibodies to hepatocyte growth factor |
| 02/24/2009 | US7494649 Drug conjugate composition |
| 02/24/2009 | US7494648 Isolated monoclonal antibody produced by the hybridoma; primary tumors and tumor metastases |
| 02/24/2009 | US7494647 Chimeric immunoglobulin for prevention and treatment blood, tumor, cardiovascular and urogenital disorders |
| 02/24/2009 | US7494646 Antibodies and molecules derived therefrom that bind to STEAP-1 proteins |
| 02/24/2009 | CA2415364C Diagnostic and therapeutic methods based on the l1 adhesion molecule for ovarian and endometrial tumors |
| 02/24/2009 | CA2370372C Porcine reproductive and respiratory syndrome vaccine, based on isolate ja-142 |
| 02/24/2009 | CA2360437C Method of acquiring immunological tolerance |
| 02/24/2009 | CA2312943C Constitutive expression of non-infectious hiv-like particles |
| 02/24/2009 | CA2247820C Functionalized nanotubes |
| 02/24/2009 | CA2245497C Peptide immunogens for vaccination against and treatment of allergy |
| 02/24/2009 | CA2214633C Antibody purification by low-ph hydrophobic interaction chromatography |
| 02/24/2009 | CA2194236C Helicobacter proteins and vaccines |
| 02/24/2009 | CA2177668C Mammalian vaccine compositions comprising squalene or squalane, glycerol and a surfactant as an adjuvant |
| 02/24/2009 | CA2152949C Vaccine preparations |
| 02/19/2009 | WO2009023877A2 Formulations for treatment of ocular diseases or conditions |
| 02/19/2009 | WO2009023819A2 Toll like receptor modulators |
| 02/19/2009 | WO2009023714A2 Compositions and methods for the treatment and prophylaxis of hypertension |
| 02/19/2009 | WO2009023549A2 Vaccine against botulism |
| 02/19/2009 | WO2009023540A1 High affinity human antibodies to human nerve growth factor |
| 02/19/2009 | WO2009023411A1 Compositions and methods for treating or controlling anterior- and posterior-segment ophthalmic diseases |
| 02/19/2009 | WO2009023360A2 Bacterial packaging strains useful for generation and production of recombinant double-stranded rna nucleocapsids and uses thereof |
| 02/19/2009 | WO2009023311A2 Transcutaneous delivery of therapeutic agents |
| 02/19/2009 | WO2009023308A2 Genetically modified babesia parasites expressing protective tick antigens and uses thereof |
| 02/19/2009 | WO2009023300A2 Mutants of cholesterol-dependent cytolysins and uses thereof |
| 02/19/2009 | WO2009023266A1 Generation of antibodies to cell-surface receptors and cancer-associated proteins including egfr family members |
| 02/19/2009 | WO2009023265A1 Monoclonal antibody 175 targeting the egf receptor and derivatives and uses thereof |
| 02/19/2009 | WO2009023164A2 Induction of mucosal immunity |
| 02/19/2009 | WO2009023043A1 Immunoglobulins directed to bacterial viral and endogenous polypeptides |
| 02/19/2009 | WO2009022652A1 Lck-derived peptide useful for cancer vaccine therapy on cancer patient who is positive for hla-a3 supertype allele |
| 02/19/2009 | WO2009022328A2 Regulators of mmp-9 and uses therof |
| 02/19/2009 | WO2009022216A2 Rna sequence motifs in the context of defined internucleotide linkages inducing specific immune modulatory profiles |
| 02/19/2009 | WO2009022162A1 Bacillus with inactivated or downregulated htra and/or htrb |
| 02/19/2009 | WO2009022157A2 Peptide with improved solubility |
| 02/19/2009 | WO2009022156A2 Peptides for desensibilization against allergens |
| 02/19/2009 | WO2009022155A2 Peptide with reduced dimer formation |
| 02/19/2009 | WO2009022154A2 Peptide with multiple epitopes |
| 02/19/2009 | WO2009021982A1 Dendritic cells |